Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma

NCT02722733 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions

DRUG: G-CSF (filgrastim)
DRUG: Cytosine arabinoside with G-CSF (filgrastim)

Sponsor

Maria Sklodowska-Curie National Research Institute of Oncology